Trial Profile
A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Aug 2012
Price :
$35
*
At a glance
- Drugs Ifosfamide (Primary) ; Sorafenib (Primary)
- Indications Osteosarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 09 May 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 18 Feb 2011 Actual end date (November 2010) added as reported by ClinicalTrials.gov.
- 18 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.